Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNFα) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNFα and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.